2022-08-25. LOVE Pharma Inc. (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has provided a shareholders’ update.
Zach Stadnyk, CEO, stated: “We welcome this opportunity to provide our shareholders with a comprehensive picture of Love’s efforts in building upon its existing portfolio and establishing its future strategic imperatives. Building upon LOVE’s existing product portfolio, which is primarily over the counter, the Company’s strategic imperative is aimed at positioning LOVE as a leader in the area of addiction treatment and recovery, within the pharmaceutical space. LOVE is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with intent to grow its Pharmaceutical presence in underserved addiction treatment market.”

#LovePharmaInc #sexualhealth #newsalert #healthnews #investmentpitchmedia

source